The intracellular HBV DNAs as novel and sensitive biomarkers for the clinical diagnosis of occult HBV infection in HBeAg negative hepatocellular carcinoma in China

PLoS One. 2014 Sep 17;9(9):e107162. doi: 10.1371/journal.pone.0107162. eCollection 2014.

Abstract

This study aimed to investigate the virological status in liver (both tumor and adjacent non-tumor tissue), the clinical features and the contribution of occult HBV infection (OBI) to postoperative prognosis in HBeAg-negative(-) hepatocellular carcinoma (HCC) patients in China. Using quantitative TaqMan fluorescent real-time PCR assays, HBV covalently closed circular DNA (cccDNA) and total DNA (tDNA) were both quantified in 11 (HBsAg(-)) and 57 (HBsAg-positive(+)) pairs of tumor tissue (TT) and adjacent non-tumor tissue (ANTT) obtained from HBeAg(-) HCC patients who received no antiviral treatment and were negative for anti-HCV before surgical treatment. Of 11 HBsAg(-) patients, 36% were with HBsAb(+) HBeAb(+) HBcAb(+). However, only 9% of the HBsAg(-) patients were HBsAb(-) HBeAb(+) HBcAb(+), which accounted for the majority (93%) in the HBsAg(+) group. TT and ANTT HBV tDNAs in 11 HCC patients with HBsAg (-) and HBeAg (-) were all detectable. HBV cccDNA and tDNA were all lower in the HBsAg(-) group than those in the HBsAg(+) group. By Kaplan-Meier analysis, patients with OBI were associated with a lower risk of cirrhosis and better overall survival (OS). The intracellular HBV DNAs, such as HBV cccDNA and tDNA are valuable biological markers for the diagnosis of occult HBV infection in HCC patients. This would assist the clinical implementation of a more personalized therapy for viral re-activation control and improve the survival rate of OBI patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Carcinoma, Hepatocellular / immunology
  • Carcinoma, Hepatocellular / mortality
  • Carcinoma, Hepatocellular / pathology
  • Carcinoma, Hepatocellular / surgery
  • Carcinoma, Hepatocellular / virology*
  • China
  • DNA, Circular
  • DNA, Viral*
  • Hepatitis B / diagnosis*
  • Hepatitis B / immunology
  • Hepatitis B / mortality
  • Hepatitis B / virology*
  • Hepatitis B Surface Antigens / blood
  • Hepatitis B Surface Antigens / immunology
  • Hepatitis B e Antigens / blood
  • Hepatitis B e Antigens / immunology
  • Hepatitis B virus / genetics*
  • Hepatitis B virus / immunology
  • Humans
  • Kaplan-Meier Estimate
  • Liver / immunology
  • Liver / pathology
  • Liver / virology
  • Liver Cirrhosis / etiology
  • Liver Cirrhosis / mortality
  • Liver Neoplasms / immunology
  • Liver Neoplasms / mortality
  • Liver Neoplasms / pathology
  • Liver Neoplasms / surgery
  • Liver Neoplasms / virology*
  • Viral Load

Substances

  • Biomarkers
  • DNA, Circular
  • DNA, Viral
  • Hepatitis B Surface Antigens
  • Hepatitis B e Antigens

Grants and funding

This study was supported by China National Key Projects for Infectious Disease (No. 2012ZX10002-016); National Natural Science Foundation of China (No. 81271925, No. 81171664); Key Projects of Science and Technology Commission of Shanghai Municipality (No. 10411955200). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.